New ACS Guidelines: Updated Colorectal Cancer Screening Recommendations

The American Cancer Society (ACS) has issued its first major update to colorectal cancer (CRC) screening guidelines since 2018, responding to the rising incidence of early-onset cases and the emergence of new diagnostic technologies. The updated guidance emphasizes the critical importance of detecting precancerous lesions—not just cancer itself—to effectively reduce mortality rates. By prioritizing tests with high sensitivity for advanced precancerous lesions, the ACS aims to shift the focus from reactive treatment to proactive prevention.

A significant portion of the update addresses the role of blood-based liquid biopsies. While these tests offer a convenient, non-invasive alternative to traditional methods, the ACS advises caution, labeling them as a secondary option for patients who refuse or cannot complete preferred screening tests. The organization cites concerns regarding lower sensitivity for early-stage lesions and declining specificity in older populations, which can lead to unnecessary follow-up procedures. The guidelines underscore that while blood tests are better than no screening at all, they currently lack the diagnostic precision required to be a primary recommendation.

Conversely, the guidelines elevate two new stool-based tests—ColoSense and Cologuard Plus—to "preferred" status. Both tests, which received FDA approval in 2024, demonstrate high sensitivity for detecting both colorectal cancer and advanced adenomas. By integrating advanced biomarker analysis, these tools provide a more robust screening option for patients. This update is vital for public health, as it provides clinicians and patients with clearer, evidence-based pathways to navigate the evolving landscape of cancer prevention, ultimately aiming to curb the concerning trends in CRC diagnoses among younger adults.